emyria

(ASX:EMD)



A ***clinical stage*** biotech, informed by the ***patient experience***, focused on unmet needs in ***neuroscience*** and ***mental health***

February 2023

Company Overview

DISCLAIMER

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Presentation release authorised by Michael Winlo, CEO and Managing Director

emyria

© Emyria 2023

MDMA & PSILOCYBIN NOW RECOGNISED AS **“MEDICINES”** BY TGA

*“For approval to prescribe, psychiatrists will need to demonstrate **appropriate training,** patient selection, **evidence-based treatment protocols** and **patient monitoring**.*

*Further, ongoing **psychotherapeutic support remains an essential component** of the psychedelic treatment model.”*

-RANZCP *(College of Psychiatrists)*

The Royal Australian & New Zealand College of Psychiatrists



Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

emyria

emyria

Advancing MDMA & CBD to address unmet needs in CNS and Mental Health

(EMD : ASX **)**

[1] ***Tenmile*** *= Health-focused investment fund of the Forrest Family*

CLINICAL FOCUS

Neuroscience & Mental Health



COMPARATIVE ADVANTAGES

- **Strong register - Tenmile[1] 7.8% / Directors 27% / Top 50 70+%**
- **Proprietary Real-World Data** - informs clinical development
- **Front-line clinical delivery *(Emerald Clinics)*** - provides patient access
- **Unique Ultra-Pure CBD formulations** - delivers clinical advantages
- **Novel MDMA-inspired chemical entities** - substantial preclinical assets
- **Global leadership team & partners** with drug registration successes

LEADING PROGRAMS & TRACTION

ULTRA-PURE CANNABINOID MEDICINES

- *First dose form (EMD-RX5) in **Phase 3 clinical trials** (ACTRN: 12622001319763)*
- Proprietary "RX" formulation high bioavailability, safety & tolerability, consistent release of cannabinoid-based medicines
- Multiple global drug registration opportunities; FDA-compliant formulation

MDMA-INSPIRED MEDICINES

- One of **world's largest libraries of unique entities** inspired by MDMA developed in partnership with University of Western Australia
- TGA accepts MDMA as Schedule 8; positioned to lead **MDMA-assisted therapy delivery** in Australia via specialist partner network

IP & PROTECTION

Growing patent library covering **novel formulations**, **methods of treatment** and **new chemical entities**

HIGHLIGHTS OF emyria BUSINESS STRUCTURE | & ASSETS

CARE → DATA → TREATMENTS

emerald clinics

Specialist cannabinoid clinics deliver care for 1,000's of patients across Australia for a wide range of clinical indications.

emyria

With the TGA rescheduling of MDMA and psilocybin, Emyria is establishing a *network of specialists* to support **psychedelic-assisted therapy**

emyria

REAL-WORLD DATA

Supports development of novel treatments

ULTRA-PURE CBD

EMD-RX5 (low-dose, synthetic CBD for over-the-counter indications) **IN PHASE 3**

EMD-RX7 (high-dose synthetic CBD for prescription indications **SCOPING PHASE 1**

MDMA-INSPIRED THERAPIES

ADVANCED MDMA ANALOGUE LIBRARY being developed with the University of Western Australia. Pursuing **faster-MDMA,** and treatments for movement disorder **IN PRECLINICAL SCREENING**

EMYRIA'S MODEL DE-RISKS & **ACCELERATES** DRUG DISCOVERY

TRADITIONAL DRUG DEVELOPMENT (costly, time-intensive, high-risk) →

Discovery → Target Validation → Lead Optimisation → Preclinical Development → Phase 1 Clinical Trial → Phase 2 Clinical Trial → Phase 3 Clinical Trial → FDA Registration

25% success **7% success**

EMYRIA'S DRUG DEVELOPMENT APPROACH (Gather insights with patients to de-risk & accelerate drug development) → *time*

Discovery & Preclinical Validation → Dose form Innovation → Phase 1/2 Clinical trial → Phase 2/3 Clinical trial → FDA Registration

Real-World Data insights from **8,000+ patients**

Informs indication selection and trial design

Ultra-Pure Cannabinoids → RX7 → RX5

MDMA analogues

LEADERSHIP | GLOBAL DRUG DEVELOPMENT & COMMERCIALISATION SUCCESSES



Dr Stewart Washer
Executive Chairman
PhD (Microbiology)

- Emyria founder, largest shareholder
- Founded multiple ASX companies
- Multiple trade sales



Prof Sir John Tooke
Non-Executive Director &
Chair of the Risk Committee
FRCP, FMedSci

- Knighted for services to medicine
- Clinician researcher - past President AMS
- Advisor to NHS on “learning health systems”



Dr Karen Smith
Executive Director
MD, PhD, MBA, LLM

- Experienced biopharma C-suite exec
- Overseen 20+ FDA approvals
- Multiple, $B+ M&A completions



Dr Michael Winlo
CEO & Managing Director
MBBS(Hons), MBA (Stanford)

- Data, trials and drug development
- Paper-to-digital at Linear
- Founding five, Palantir Health Team



C/Prof Alistair Vickery
Medical Director
MBBS, FRACGP, FCHSM

- Big Data researcher, epidemiology
- Chair of Black Swan Health
- Professor of Medicine at UWA



Matt Callahan
Non-Executive Director
LLB

- 4 FDA approvals
- Venture capital experience
- Successful exit - iCeutica to Iroko

ADVANCED CANNABINOID DEVELOPMENT



EPIDYOLEX™ | WORLD'S ONLY REGISTERED CBD OIL > $1B / YR SALES

Despite hundreds of CBD products available, only 1 product has demonstrated the **clinical effectiveness** and **product reliability** required to achieve registration with major global regulators (like the FDA), driving significant value for shareholders

1998

GW Pharma invests **>$2B** & **>50 clinical trials** [1]


2018

FDA approves Epidyolex as **"small molecule"** [2]



2021

GW **acquired** by Jazz Pharma for **USD $7.2B** [3]



KEY INSIGHTS

(1) Drug registration creates value but, requires
(2) Great evidence *(Real-World Data)* and
(3) Great products *(Ultra-Pure cannabinoids)*

We believe emyria can improve on Epidyolex oil & accelerate multiple new drug registrations

emyria

1. https://www.europeanpharmaceuticalreview.com/news/152570/highest-british-business-award-goes-to-cannabis-drug-developer-gw-pharmaceuticals/
2. GW Pharmaceuticals Annual Report June 2018
3. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-gw-pharmaceuticals-plc-creating

© Emyria 2023

MOST **CANNABINOID** PRODUCTS HAVE LIMITATIONS


CBD PRODUCTS ARE UNDIFFERENTIATED

There are more than




products in Australia, most are undifferentiated.

PRODUCT RELIABILITY IS VARIABLE [1]



What's on the label is not in the box

BIOAVAILABILITY IS POOR [2]



Your body absorbs ~6.5% of what is taken orally

Food dramatically affects absorption

KEY OPPORTUNITY

Emyria has developed a differentiated cannabinoid product that is:
1. Ultra-Pure (meets requirements for FDA registration) **2. improves bioavailability** in a **3. patient-preferred dose form.**

emyria

1. Johnson, E., Kilgore, M. & Babalonis, S. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim. J Cannabis Res 4, 28 (2022). https://doi.org/10.1186/s42238-022-00140-1
2. https://www.tga.gov.au/sites/default/files/auspar-cannabidiol-210115.pdf

© Emyria 2023



IMPROVING CBD

THE EMD-RX PLATFORM

A world-first, proprietary formulation of synthetically-derived **Ultra-Pure cannabidiol** in a capsule with high bioavailability to support multiple, global, **over-the-counter** & **prescription** registration opportunities.

EMD-RX PLATFORM

CLINICAL ADVANTAGES OVER INCUMBENTS

	EMD-RX	Vs	CBD oils *& similar preparations*
PATIENT PREFERRED FORM	**Convenient, solid oral capsules** (no spilling)		**Majority of products** are oil preparations
ULTRA PURITY	**No detectable** *THC* **No detectable** *impurities*		**Small quantities of** *THC* **Small quantities of** *impurities*
SAFE & TOLERABLE	**Safe & well tolerated** at trial doses **No observed** gastrointestinal upset		**Adverse events at higher doses** (eg GI upset)
NOVEL IP	**Proprietary** formulation		**Most CBD oils are "me too" products with generic formulations and limited IP protections**
FDA-READY	**FDA** Drug Master File for API. *Allows Emyria to reference material to regulator without disclosing contents [1]*		Most CBD oils ***do not*** meet FDA requirements for CBD purity *(with exception of Epidyolex) [2]*
PREFERRED DOSING PROFILE	**High** bioavailability**, low inter-patient** variability **& slow release**		**Poor** bioavailability**, high patient** variability
AT CLINICAL STAGE	**In Phase 3** clinical trials		**Majority of products have** no supportive trial data



KEY INSIGHT

Emyria's proprietary, FDA-ready dose form solves a number of limitations with common CBD preparations.
EMD-RX5 is ready for multiple indications and global registration opportunities with demonstrated clinical performance.

www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs
www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

© Emyria 2023

EMD-RX5

Emyria's first Ultra-Pure, low-dose CBD capsule

In Phase 3 trials and pursuing multiple, global "over-the-counter" registration opportunities



PSYCHOLOGICAL DISTRESS IN AUSTRALIA - FIRST INDICATION FOR EMD-RX5

INITIAL CLINICAL OPPORTUNITY




2.8M
Adults with Chronic Pain

Of these, **1.4M have symptoms of Anxiety or Stress** [1]

NO OTC SOLUTION CURRENTLY EXISTS BUT, CANNABIDIOL MAY HELP:

Emyria's proprietary Real-World Data on hundreds of patients receiving low-dose CBD for 6+ months has informed our choice of target population and clinical indication.



Psychological distress comprises symptoms of anxiety, stress, sleep disturbance and GI upset with a **higher prevalence in patients with chronic disease**

- **TGA allows low-dose CBD** (<150mg/day) to be registered as an "over-the-counter", pharmacist-only, Schedule 3 (S3) medicine. [2]
- Registered S3 (OTC) treatments do not require a doctor's prescription. Australians spend **$5b/year on OTC medicines** [3]
- 150mg of CBD currently costs between $250 and $800 per month. All out-of-pocket. Large opportunity to develop an affordable OTC, CBD medicine.
- Emyria has multiple 'methods of use' patents to cover use of low-dose CBD across a range of appropriate indications.

emyria

1. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics
2. See ASX announcement 16 December 2021 3. Medicines in the health system, Australian Institute of Health and Welfare (2022)


© Emyria 2023

EMD-RX5 | **ULTRA-PURE CBD** *CAPSULE* **VS** EPIDYOLEX™ *OIL*

In a key, head-to-head study, **EMD-RX5** was safe, well tolerated and demonstrated:
(1) high bioavailability (2) slow release profile (3) lower dose variability and







EMD-RX5 pursuing registration with TGA:

In active Phase 3 clinical trials
due to complete H2, 2023

Ultra Pure CBD with a Drug Master File (DMF)
allows assessment as "small molecule" with FDA after TGA registration

Suitable for multiple registration opportunities
Ready for indication, and geographic, expansion

emyria


WHAT'S NEXT? | GROW MARKET FOR **EMD-RX5** *(ADD INDICATIONS, EXPAND GEOGRAPHY)*

An **Ultra-Pure cannabinoid** product makes it possible to pursue registration beyond Australia in jurisdictions where product purity rules are stricter. With the support of Emyria's proprietary Real-World Data, **EMD-RX5 has multi-indication potential**.

AUSTRALIA
Adult Population
= 20 million

EU
Adult Population
= 360 million

USA
Adult Population
= 260 million



Emyria's Ultra-Pure dose form & Real-World Data supports growth through indication and geographic expansion.

1. See ASX announcement 16 December 2021 2. Canavan, C., West, J. and Card, T., 2014. The epidemiology of irritable bowel syndrome. Clinical epidemiology, 6, p.71.
3.Grandner, M.A., Martin, J.L., Patel, N.P., Jackson, N.J., Gehrman, P.R., Pien, G., Perlis, M.L., Xie, D., Sha, D., Weaver, T. and Gooneratne, N.S., 2012. Age and sleep disturbances among American men and women: data from the US Behavioral Risk Factor Surveillance System. Sleep, 35(3), pp.395-406.
4. National Study of Mental Health and Wellbeing 2020-21 series, Australian Bureau of Statistics

emyria

© Emyria 2023

WHAT'S NEXT? | LAUNCH PRESCRIPTION-STRENGTH CBD (**EMD-RX7**)




Chart shows concentrations of CBD in the blood for 3 different formulations as measured over a 24 hour period in an animal model.

Each formulation compared the same amount of CBD - 50mg.

EMD-RX7 showed <u>more than 4 times</u> the bioavailability of Epidyolex and is now being prepared for Phase 1 clinical trials to support prescription indications where higher doses of Ultra-Pure CBD are indicated. [1]

Emyria has been accepted into the NIH's preclinical screening platform for pain (PSPP) to further evaluate EMD-RX7 for pain indications. [2]

Additional, FDA-focused indications are in planning via 505(b)2 pathway.




KEY INSIGHT **HIGHER BIOAVAILABILITY CBD** has potential to support multiple, global prescription registrations

1. See ASX announcement 17 March 2022
2. See ASX announcement 28 November 2022

© Emyria 2023

WHAT'S NEXT? | ADVANCED CANNABINOID DEVELOPMENT



Emyria has been accepted into the NIH's preclinical screening program for pain. This is a **fully funded program.** *See ASX release 28 Nov 2022*



MDMA-INSPIRED
THERAPY INNOVATION

POST-TRAUMATIC STRESS DISORDER

USA



US$232B

Total economic burden [1]

US$25,684 annual cost of PTSD per military personnel and veterans, *(versus US$18,640 per civilian)*

AUSTRALIA



1M with PTSD [2]

Up to **500K** "Treatment Resistant"


emyria

1. https://www.psychiatrist.com/jcp/trauma/ptsd/economic-burden-posttraumatic-stress-disorder-united-states-societal-perspective/
2. https://www.phoenixaustralia.org/research/research-publications/

© Emyria 2023

MDMA-ASSISTED THERAPY FOR **PTSD** | PROMISING RESULTS

Treatment response and remission for MDMA and Placebo groups as a percentage of total participants randomised to each arm (MDMA, *n* = 46; Placebo, *n*= 44).



Responders (clinically significant improvement, defined as a ≥10-point decrease on CAPS-5), loss of diagnosis (specific diagnostic measure on CAPS-5), and remission (loss of diagnosis and a total CAPS-5 score of ≤11) were tracked in both groups. Non-response is defined as a <10-point decrease on CAPS-5. Withdrawal is defined as a post-randomization early termination.

In a **landmark Phase 3 study** (n=91) [1], patients with PTSD *(average of 15 years severe illness)* were randomised to receive MDMA-assisted therapy or therapy with placebo.

67% Of participants in the MDMA group **no longer met the PTSD diagnosis criteria** following 3 sessions of MDMA-assisted therapy, compared to **32%** in the therapy-only group.

MAPS has recently completed a second Phase 3 and is preparing for FDA registration. [3]

1. Trial of MDMA-assisted therapy for severe PTSD, Multidisciplinary Association for Psychedelic Studies (MAPS), 2021
2. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021 Jun;27(6):1025-33
3. https://mapspublicbenefit.com/press-releases/mapp2-completion-announcement/

© Emyria 2023


MDMA & PSILOCYBIN NOW RECOGNISED AS **“MEDICINES”** BY TGA

*“For approval to prescribe, psychiatrists will need to demonstrate **appropriate training,** patient selection, **evidence-based treatment protocols** and **patient monitoring**.*

*Further, ongoing **psychotherapeutic support remains an essential component** of the psychedelic treatment model.”*

-RANZCP *(College of Psychiatrists)*

The Royal Australian & New Zealand College of Psychiatrists



Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration


From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

Assisting psychiatrists prepare is a HUGE CHALLENGE to patient access
emyria is uniquely positioned to create value in this new regulatory environment via:

(1) Facilitating Patient Delivery & (2) Novel Drug Discovery


1) **SUPPORT** PATIENT DELIVERY

MDMA-INSPIRED MEDICINES



© Emyria 2023

2) **CREATE** "NEXT-GENERATION" **MDMA**



MDMA is a small, stable, brain-penetrating molecule that increases the release of 3 primary neurotransmitters

1

Serotonin
thought to contribute to feelings of *well-being*

2

Dopamine
associated with feelings of *pleasure and satisfaction*

3

Noradrenaline
affects attention and related to *"fight or flight" response*

MDMA has many points of diversification creating opportunities to tune selectivity for key neurotransmitters and generate novel chemical entities with broad therapeutic potential

POTENTIAL THERAPEUTIC APPLICATIONS FOR ADVANCED ANALOGUES

- Avoid potentially toxic metabolites
- Moderate stimulatory & euphoric effects
- Faster-acting compounds
- Fewer drug-drug interactions

emyria


© Emyria 2023


MDMA-INSPIRED DRUG DISCOVERY | WORKFLOW

NEW DRUG DISCOVERY

with THE UNIVERSITY OF WESTERN AUSTRALIA

Take MDMA as inspiration → **Design & synthesise new analogues** → **Advanced screening** → **Prioritise indications**





Proprietary analogue library

>140 novel chemical entities and growing

- Pharmacology (target) screens
- Safety screens
- Behavioural studies
- Metabolism assays
- Peripheral effects

Mental health
(Next-gen MDMA)

Movement disorders
(Neuro treatments)

Non-neurological
(Fibrotic diseases)

emyria

© Emyria 2023

MDMA-INSPIRED DRUG DISCOVERY | MULTIPLE $B OPPORTUNITIES

Clinical focus	Role of MDMA?	Goals for analogue program	Early proof-of-concept?	What's next?
***Treatment Resistant* PTSD** (5% adults, 30-50% treatment resistant) **Costs of $25B/year**	MDMA increases feelings of *compassion* and *sociability* while reducing *fear* & *defensiveness*. Phase 3 trials have shown MDMA-assisted therapy can have a profound benefit [1]	**Faster-acting MDMA** with improved tolerability can increase the potential pool of patients with potential to benefit	Sub-set of analogues show faster rates of metabolism,	Advanced screening to identify rapidly metabolised compounds
***L-DOPA induced dyskinesia* in Parkinson's Disease** (40% of PD patients at 4 years of treatment) **Costs of $1B/year**	MDMA has been shown to improve the "on-time' (beneficial effects) of L-DOPA but has numerous, unwanted side-effects [2]	**Remove the "high" from MDMA** while preserving beneficial effects on movement disorders.	Gold-standard preclinical model demonstrates analogues can increase on-time by 200%. C/W recently approved PBS drug (Ongentys) which increases on-time by 1hr/24hrs	Advance new compounds Long-term safety and tolerability studies
Fibrotic disease (1.2M patients globally) **Costs of $3B/year**	Some analogues can induce fibrosis. Can MDMA analogues be developed to *reduce* it?	**Identify compounds with 5HT2B antagonism** (a known target for anti-fibrosis medicines)	Cell assays demonstrate reduced collagen deposition at test concentrations.	Further proof-of-concept studies to identify lead compounds

1. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021 Jun;27(6):1025-33


emyria

© Emyria 2023

MDMA ANALOGUE HIGHLIGHT | FASTER-ACTING MDMA

Potential Target: MDMA-ASSISTED THERAPY FOR MENTAL HEALTH

Recent in vitro metabolic studies of Emyria's analogues demonstrate that our library has compounds with diverse half-lives, suggesting it ***may*** be *possible to generate MDMA analogues* with **much faster,** and *slower* onset of action.



Note: These in vitro studies approximate liver-led metabolism of drugs. Other potential metabolic pathways *(and other clearance pathways)* not represented in microsomes are not evaluated.

NEXT STEPS:

- Functional assays to identify novel compounds most like MDMA
- Further in vitro metabolic screening to approximate half-life

emyria

© Emyria 2023


MDMA-INSPIRED DRUG DISCOVERY | WHAT'S NEXT?

NEW DRUG DISCOVERY

with THE UNIVERSITY OF WESTERN AUSTRALIA

IN THE NEXT 12 MONTHS, EMYRIA INTENDS TO:

- **DELIVER RESULTS** from multiple preclinical programs on select MDMA analogues
- **SELECT LEADS** by proof-of-concept efficacy studies in animal models
- **EXPAND** the MDMA-analogue library
- **FILE** additional patent families and pursue commercialisation discussions



emyria

© Emyria 2023

emyria INVESTMENT **HIGHLIGHTS**

1

Proprietary formulations of Ultra-Pure CBD

First dose form in **Phase 3 trials**

Platform is **partnership ready**

No THC or impurities

High bioavailability low dose variability & slower release

Supports **multiple indications**

2

Proprietary **Real World Data (RWD) engine**

Emyria's clinical service, **Emerald Clinics**, has gathered the world's largest data set with patients guiding indication selection, **cannabinoid** dose form development and pivotal clinical trial designs. Will now be applied to **MDMA therapies**

3

MDMA now recognised as "medicine"

Changing regulatory environment creates opportunity to establish a **national network** to provide data that can support the MDMA analogue program

4


Substantial R&D pipeline

One of world's largest MDMA analogue libraries - novel, small, stable, brain-penetrating and neuroactive molecules with potential to become novel neuropsychiatric treatments.

5

World-class team with multiple FDA registrations

Emyria's in-house expertise covers drug development, clinical trials, drug registration, data analysis and patient care.



CONTACT INFORMATION

Michael Winlo	mwinlo@emyria.com
Investors	investors@emyria.com
Media	media@emyria.com
General	info@emyria.com